<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Gastroenterol</journal-id><journal-id journal-id-type="iso-abbrev">J. Gastroenterol</journal-id><journal-title-group><journal-title>Journal of Gastroenterology</journal-title></journal-title-group><issn pub-type="ppub">0944-1174</issn><issn pub-type="epub">1435-5922</issn><publisher><publisher-name>Springer Japan</publisher-name><publisher-loc>Tokyo</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24005956</article-id><article-id pub-id-type="pmc">3895197</article-id><article-id pub-id-type="publisher-id">875</article-id><article-id pub-id-type="doi">10.1007/s00535-013-0875-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article&#x02014;LIVER, PANCREAS, AND BILIARY TRACT</subject></subj-group></article-categories><title-group><article-title>Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-na&#x000ef;ve hepatitis C genotype 1-infected patients in Japan: the DRAGON study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Hayashi</surname><given-names>Norio</given-names></name><address><phone>+81-6-64161221</phone><fax>+81-6-64191870</fax><email>hayashin@kanrou.net</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Seto</surname><given-names>Chiharu</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Kato</surname><given-names>Mai</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Komada</surname><given-names>Yuji</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Goto</surname><given-names>Shoichiro</given-names></name><address><email>sgoto2@its.jnj.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff1"><label/>Kansai Rosai Hospital, 1-69 Inabasou 3-chome, Amagasaki-shi, Hyogo Japan </aff><aff id="Aff2"><label/>Research and Development, Clinical Science Division, Janssen Pharmaceutical K.K., Tokyo, Japan </aff><aff id="Aff3"><label/>Research and Development, Japan Clinical Operations Division, Janssen Pharmaceutical K.K., Tokyo, Japan </aff></contrib-group><pub-date pub-type="epub"><day>5</day><month>9</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>5</day><month>9</month><year>2013</year></pub-date><pub-date pub-type="ppub"><year>2014</year></pub-date><volume>49</volume><issue>1</issue><fpage>138</fpage><lpage>147</lpage><history><date date-type="received"><day>18</day><month>6</month><year>2013</year></date><date date-type="accepted"><day>21</day><month>8</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2013</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>
Efficacy, safety and pharmacokinetics of simeprevir (TMC435), a once-daily, noncovalent, oral hepatitis C virus (HCV) NS3/4A protease inhibitor, was evaluated in combination with peginterferon &#x003b1;-2a/ribavirin (PegIFN&#x003b1;-2a/RBV) for treatment-na&#x000ef;ve, HCV genotype&#x000a0;1-infected patients in Japan.</p></sec><sec><title>Methods</title><p>In a multicenter, randomized clinical trial in Japan, ninety-two patients received either simeprevir (50 or 100&#x000a0;mg QD) for 12 or 24&#x000a0;weeks with PegIFN&#x003b1;-2a/RBV for 24 or 48&#x000a0;weeks (according to response-guided therapy [RGT] criteria), or PegIFN&#x003b1;-2a/RBV for 48&#x000a0;weeks (PR48 group).</p></sec><sec><title>Results</title><p>Compared with the PR48 group, plasma HCV RNA reductions in the simeprevir groups were rapid and more substantial (Week 4: &#x02212;5.2, &#x02212;5.2 and &#x02212;2.9 log<sub>10</sub>IU/mL for simeprevir 50&#x000a0;mg combined, 100&#x000a0;mg combined, and PR48 groups, respectively). High rapid virologic response rates (83, 90, and 8&#x000a0;% for simeprevir 50&#x000a0;mg combined, 100 mg combined, and PR48 groups, respectively) led to high sustained virologic response rates (77&#x02013;92&#x000a0;%, compared with 46&#x000a0;% for PR48). All but one of the simeprevir-treated patients were eligible to complete treatment after 24&#x000a0;weeks (RGT). Relapse rates in simeprevir-treated patients were low (8&#x02013;17&#x000a0;%, compared with 36&#x000a0;% for the PR48 group). There were no notable differences in the safety profile between the simeprevir and PR48 groups.</p></sec><sec><title>Conclusions</title><p>The addition of simeprevir QD to PegIFN&#x003b1;-2a/RBV, as compared with PegIFN&#x003b1;-2a/RBV alone, demonstrated potent antiviral activity and significantly improved the rates of sustained virologic response, with a shortened 24-week treatment duration, in treatment-naive patients infected with HCV genotype 1 in Japan. Simeprevir was generally safe and well tolerated. (ClinicalTrials.gov number, NCT00996476).</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s00535-013-0875-1) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Chronic hepatitis C</kwd><kwd>Protease inhibitor</kwd><kwd>Direct-acting antiviral</kwd><kwd>Sustained virologic response</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Japan 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>The hepatitis C virus (HCV) is a leading cause of chronic liver disease worldwide infecting an estimated 130&#x02013;170 million people, or 2.2&#x02013;3.0&#x000a0;% of the global population [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. In Japan, hepatocellular carcinoma (HCC) is one of the most common causes of cancer mortality (incidence of 7&#x000a0;% in Japan, compared with 1&#x02013;4&#x000a0;% in Europe and the USA [<xref ref-type="bibr" rid="CR3">3</xref>]) and 79&#x000a0;% of HCC cases are due to HCV infection [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. An estimated 2&#x000a0;million Japanese people are infected, 70&#x000a0;% with HCV genotype 1b, 20&#x000a0;% with genotype 2a, and the remainder with genotype 2b or other genotypes [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p>Until recently, the standard of care for the treatment of chronic genotype 1 HCV infection was a combination of peginterferon (PegIFN&#x003b1;-2a) and ribavirin (RBV) for 48&#x000a0;weeks or longer [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. However, the long treatment duration is a substantial physical and mental burden for patients, and rates of treatment discontinuation and dose reduction due to adverse events (AEs) are high [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Furthermore, sustained virologic response (SVR, defined as undetectable HCV&#x000a0;RNA at a given time point after the end of treatment) is achieved in only 42&#x02013;52&#x000a0;% of patients [<xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. Novel, direct-acting antiviral agents (DAAs) are therefore under development. Two first-generation HCV NS3/4A protease inhibitors (PIs), boceprevir [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>] and telaprevir [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], have recently been approved for the treatment of genotype 1-infected patients in the USA and Europe, and telaprevir is also approved in Japan [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. The inclusion of these agents in HCV treatment regimens has led to large improvements in SVR rates, though these agents require dosing three times daily (every 7-9&#x000a0;h) and their use is associated with increased incidence and, in some cases, severity of AEs such as anemia and rash [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR18">18</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>].</p><p>Simeprevir (TMC435) is an investigational, once-daily (QD) oral NS3/4A protease inhibitor currently under clinical development globally. International Phase IIb trials of simeprevir in combination with PegIFN&#x003b1;-2a/RBV for treatment-na&#x000ef;ve and -experienced patients infected with HCV genotype 1 demonstrated that simeprevir was generally well tolerated, had a pharmacokinetic profile that supports QD dosing and resulted in high virologic response rates [<xref ref-type="bibr" rid="CR22">22</xref>&#x02013;<xref ref-type="bibr" rid="CR25">25</xref>].</p><p>In a Phase I study in 30 healthy Japanese adult male volunteers living in the USA (TMC435-C109; NCT00752544), simeprevir was generally well tolerated. Simeprevir plasma exposures were higher in Japanese healthy volunteers compared with Caucasian volunteers in the TMC435-C101 study (NCT00938899) [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p>The Dose and duration Ranging study of Antiviral agent TMC435 in Genotype One HCV treatment-Na&#x000ef;ve patients (DRAGON; TMC435-C215) was a Phase II study conducted across Japan to evaluate the efficacy, safety and pharmacokinetics of simeprevir and PegIFN&#x003b1;-2a/RBV in treatment-na&#x000ef;ve, HCV-infected patients. Based on the higher exposure of simeprevir in Japanese versus Caucasian healthy volunteers demonstrated in the Phase I study, simeprevir doses of 50 and 100&#x000a0;mg QD were selected for evaluation in this dose-ranging, Japanese Phase II study.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Patients</title><p>Patients recruited to the DRAGON study were treatment-na&#x000ef;ve, chronically infected with genotype 1 HCV, aged 20&#x02013;70&#x000a0;years and had plasma levels of HCV&#x000a0;RNA &#x02265;5.0&#x000a0;log<sub>10</sub>&#x000a0;IU/mL at screening.</p><p>Key exclusion criteria included: (1) presence of liver cirrhosis or hepatic failure, or other liver disease, (2) infection/co-infection with HIV-1, HIV-2, hepatitis B or nongenotype 1 HCV, (3) malignant tumor within 5&#x000a0;years prior to study, (4) HCC, (5) meeting conditions that required caution with PegIFN&#x003b1;-2a or RBV treatment, (6) any clinically significant disease, (7) organ transplant, and (8) defined laboratory abnormalities during screening.</p></sec><sec id="Sec4"><title>Study design</title><p>The DRAGON study was a multicenter, randomized, open-label, parallel group comparison study performed to evaluate the efficacy, safety and pharmacokinetics of simeprevir in combination with PegIFN&#x003b1;-2a/RBV in treatment-na&#x000ef;ve patients with chronic genotype 1 HCV infection. The study was performed from July 6, 2009, to April 1, 2011, in accordance with the Declaration of Helsinki, and was consistent with Good Clinical Practice guidelines and applicable regulatory requirements. The study protocol and amendments were reviewed by Institutional Review Boards and each patient provided written informed consent.</p><p>Eligible patients were randomized to one of five treatment groups (SMV12/PR24 50&#x000a0;mg, SMV24/PR24 50&#x000a0;mg, SMV12/PR24 100&#x000a0;mg, SMV24/PR24 100&#x000a0;mg and PR48) in a 2:1:2:1:1 ratio. In the SMV12/PR24 50&#x000a0;mg and SMV12/PR24 100&#x000a0;mg groups, patients received simeprevir (50 or 100 mg QD, respectively) combined with PegIFN&#x003b1;-2a/RBV for 12&#x000a0;weeks, followed by PegIFN&#x003b1;-2a/RBV for 12&#x000a0;weeks. In the SMV24/PR24 50&#x000a0;mg and SMV24/PR24 100&#x000a0;mg groups, patients received simeprevir (50 or 100&#x000a0;mg&#x000a0;QD, respectively) combined with PegIFN&#x003b1;-2a/RBV for 24&#x000a0;weeks. In these four groups, at week 24, patients either stopped or continued treatment with PegIFN&#x003b1;-2a/RBV up to week 48, according to response-guided therapy (RGT) criteria (stop treatment if plasma HCV&#x000a0;RNA &#x0003c;1.4 log<sub>10</sub> IU/mL at week 4 and undetectable at weeks 12, 16 and 20, otherwise continuing PegIFN&#x003b1;-2a/RBV to week 48). In the PR48 group, criteria were not applied; patients received PegIFN&#x003b1;-2a/RBV for 48&#x000a0;weeks.</p><p>Major efficacy endpoints included the proportion of patients with undetectable plasma HCV&#x000a0;RNA 24&#x000a0;weeks after the end of treatment (SVR24). Other efficacy endpoints included the proportion of patients with undetectable plasma HCV RNA at week 4 (rapid virologic response; RVR) or week 12 (complete early virologic response, cEVR) and change in plasma HCV&#x000a0;RNA level from baseline to week 4 of treatment. Incidence of viral breakthrough (increase of &#x0003e;1 log<sub>10</sub> IU/mL in plasma HCV RNA level from the lowest level reached, or plasma HCV&#x000a0;RNA level of &#x0003e;2.0 log<sub>10</sub> IU/mL in patients whose plasma HCV&#x000a0;RNA level had previously been below 1.4 log<sub>10</sub>&#x000a0;IU/mL or undetectable), viral relapse (detectable plasma HCV RNA during the post-treatment follow-up period in patients who had undetectable plasma HCV RNA at the end of treatment) and the viral NS3 sequence were also assessed.</p><p>According to predefined virologic stopping rules, patients in the simeprevir groups discontinued simeprevir and continued PegIFN&#x003b1;-2a/RBV if viral breakthrough occurred during the first 24&#x000a0;weeks, and stopped all treatment if the decrease in plasma HCV RNA from baseline to week 12 was &#x0003c;2 log<sub>10</sub>&#x000a0;IU/mL, or plasma HCV RNA level at week 24 was &#x02265;1.2&#x000a0;log<sub>10</sub>&#x000a0;IU/mL.</p><p>The population-based sequencing assay to determine HCV NS3/4A sequence based on the standard Sanger sequencing method was performed for patients with viral breakthrough and viral relapse. Sequencing data were reported as amino acid changes from Con1 (GenBank accession number AJ238799) or H77 (GenBank accession number AF009606) for genotype 1b and 1a/others, respectively.</p><p>Safety endpoints included the frequency and severity of AEs including serious AEs (SAEs), incidence of discontinuation of study drugs due to AEs, and changes in clinical laboratory test values.</p></sec><sec id="Sec5"><title>Treatment administration</title><p>Simeprevir was administered orally at a dose of 50 or 100&#x000a0;mg as a single capsule QD. No simeprevir dose reduction was permitted. PegIFN&#x003b1;-2a (Pegasys<sup>&#x000ae;</sup>, Chugai) was administered as a subcutaneous injection (180&#x000a0;&#x003bc;g once weekly) and RBV (Copegus<sup>&#x000ae;</sup>, Chugai) as oral tablets (600&#x02013;1000&#x000a0;mg total daily dose, depending on body weight) in accordance with the manufacturer&#x02019;s prescribing information for both medications. Patients were hospitalized for a minimum of 1&#x000a0;week, starting on the first day that simeprevir and PegIFN&#x003b1;-2a/RBV were administered. Treatment of anemia with erythropoietin was not permitted in the study.</p></sec><sec id="Sec6"><title>Measurements</title><p>Plasma HCV RNA was quantified upon screening, at baseline, at 4 and 8&#x000a0;h on day 1, on day 3, at weeks 1, 2, 3, 4, 6, 8, 12, 16, 20 and 24 (all patients), and weeks 28, 36 and 48 (patients stopping PegIFN&#x003b1;-2a/RBV at week 24) or weeks 28, 36, 42, 48, 52, 60 and 72 (patients receiving PegIFN&#x003b1;-2a/RBV until week 48), using the Roche COBAS<sup>&#x000ae;</sup> TaqMan<sup>&#x000ae;</sup> HCV Auto assay system (lower limit of quantification [LLOQ] 15&#x000a0;IU/mL, equivalent to 1.2 log<sub>10</sub>&#x000a0;IU/mL). Plasma HCV RNA below the LLOQ was either assigned as &#x02018;HCV RNA &#x0003c;1.2 log<sub>10</sub> IU/mL detectable&#x02019; if traces of HCV RNA were detected, or &#x02018;undetectable HCV RNA&#x02019; if no HCV RNA was detected. Alanine aminotransferase (ALT) was quantified at baseline and weeks 1, 2, 4, 6, 8, 12, 16, 20 and 24 (all patients), and weeks 28 and 48 (patients stopping at week 24), or weeks 36, 42, 48, 52 and 72 (patients receiving PegIFN&#x003b1;-2a/RBV until week 48).</p><p>Laboratory test values, results of vital sign assessment and presence or absence of electrocardiogram abnormalities were recorded at screening and at regular intervals throughout treatment and the post-treatment follow-up period. AEs were recorded throughout the study period.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p>Efficacy analyses were performed on the full analysis set (FAS; all randomized patients with post-baseline efficacy assessment data). For virologic responses (RVR, cEVR and SVR24), rates were summarized for the combined simeprevir 50&#x000a0;mg (i.e. SMV12/PR24 50&#x000a0;mg and SMV24/PR24 50&#x000a0;mg groups pooled) and 100&#x000a0;mg (i.e. SMV12/PR24 100&#x000a0;mg and SMV24/PR24 100&#x000a0;mg groups pooled) groups, and compared with that of the PR48 group. In addition, for SVR24, rates were calculated for each of the five treatment groups. The change in HCV&#x000a0;RNA from baseline to week 4 was assessed using analysis of covariance (ANCOVA), with the dose group as a factor and plasma HCV&#x000a0;RNA at baseline as a covariate, to calculate the least-squares (LS) means and two-tailed corresponding 95&#x000a0;% confidence intervals (CIs). These were calculated for change from baseline for the combined simeprevir 50&#x000a0;mg or combined simeprevir 100 mg groups and the PR48 group, and the differences between groups. Fisher&#x02019;s exact test was performed to compare RVR and cEVR between the combined simeprevir groups and the PR48 group.</p><p>A mutation was considered as emerging at a specific time point if the amino acid at a given position was absent at baseline and present at that time point. Incidence of emergent mutations at the time of viral breakthrough or relapse was summarized.</p><p>The proportion of patients displaying ALT within the normal limits was summarized for all patients in the combined simeprevir groups and for the PR48 group. Incidence of AEs and other safety endpoints were analyzed for all patients who received at least one dose of medication and were summarized per treatment group.</p></sec></sec><sec id="Sec8" sec-type="results"><title>Results</title><sec id="Sec9"><title>Patient disposition and baseline characteristics</title><p>In total, 116 patients were screened and 93 were randomized to treatment groups, of whom 92 received at least one dose of a study drug (Supplementary Fig.&#x000a0;1). Ninety-one percent of the patients completed the study. The main reasons for study discontinuation were withdrawal of consent (5&#x000a0;%) and occurrence of AEs (2&#x000a0;%). Out of seven patients who discontinued from the study during the post-treatment follow-up period, five patients dropped out due to withdrawal of consent, and two (1 in SMV12/PR24 100&#x000a0;mg group, 1 in PR48 group) due to AEs.</p><p>In the simeprevir groups, nine patients permanently discontinued all treatment due to AEs (8/79, 10&#x000a0;%) or virologic stopping criteria (1/79, 1.3&#x000a0;%). In the PR48 group, three patients permanently discontinued all treatment due to AEs (<italic>n</italic>&#x000a0;=&#x000a0;2) or another reason (<italic>n</italic>&#x000a0;=&#x000a0;1).</p><p>There were no notable differences in baseline demographic characteristics between treatment groups (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Approximately half of the patients (39 to 62&#x000a0;%) were male, with a median age of&#x000a0;54&#x000a0;years (range&#x000a0;20&#x02013;69&#x000a0;years) and median body weight of 58&#x000a0;kg (range 40&#x02013;85&#x000a0;kg). All patients were infected with HCV genotype 1b and the median baseline HCV RNA was 6.3&#x000a0;log<sub>10</sub>&#x000a0;IU/mL (range 4.5&#x02013;7.0 log<sub>10</sub>&#x000a0;IU/mL). A total of 7&#x000a0;% of patients displayed Metavir fibrosis stage 3; there were no patients with fibrosis stage 4.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Patient demographics and baseline characteristics (safety population)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">SMV12/PR24 50&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;27)</th><th align="left">SMV24/PR24 50&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;13)</th><th align="left">SMV12/PR24 100&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;26)</th><th align="left">SMV24/PR24 100&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;13)</th><th align="left">PR48 (control) (<italic>n</italic>&#x000a0;=&#x000a0;13)</th><th align="left">Total (<italic>n</italic>&#x000a0;=&#x000a0;92)</th></tr></thead><tbody><tr><td align="left">Male, <italic>n</italic> (%)</td><td char="(" align="char">12 (44)</td><td char="(" align="char">6 (46)</td><td char="(" align="char">10 (39)</td><td char="(" align="char">8 (62)</td><td char="(" align="char">7 (54)</td><td char="(" align="char">43 (47)</td></tr><tr><td align="left">Age, years, median (range)</td><td char="(" align="char">53 (31&#x02013;67)</td><td char="(" align="char">48 (34&#x02013;67)</td><td char="(" align="char">56 (22&#x02013;69)</td><td char="(" align="char">54 (28&#x02013;68)</td><td char="(" align="char">54 (20&#x02013;66)</td><td char="(" align="char">54 (20&#x02013;69)</td></tr><tr><td align="left">Age&#x000a0;&#x02264;&#x000a0;65&#x000a0;years, <italic>n</italic> (%)</td><td char="(" align="char">25 (93)</td><td char="(" align="char">12 (92)</td><td char="(" align="char">24 (92)</td><td char="(" align="char">11 (85)</td><td char="(" align="char">12 (92)</td><td char="(" align="char">84 (91)</td></tr><tr><td align="left">Weight, kg, median (range)</td><td char="(" align="char">56 (40&#x02013;81)</td><td char="(" align="char">58 (44&#x02013;80)</td><td char="(" align="char">56 (44&#x02013;85)</td><td char="(" align="char">59 (46&#x02013;83)</td><td char="(" align="char">59 (45&#x02013;81)</td><td char="(" align="char">58 (40&#x02013;85)</td></tr><tr><td align="left">Baseline HCV RNA, log<sub>10</sub> IU/mL, median (range)</td><td char="(" align="char">6.5 (4.5&#x02013;6.9)</td><td char="(" align="char">6.2 (5.3&#x02013;6.7)</td><td char="(" align="char">6.4 (5.2&#x02013;6.9)</td><td char="(" align="char">6.5 (5.8&#x02013;7.0)</td><td char="(" align="char">6.0 (5.1&#x02013;6.9)</td><td char="(" align="char">6.3 (4.5&#x02013;7.0)</td></tr><tr><td align="left">Genotype 1b, <italic>n</italic> (%)</td><td char="(" align="char">27 (100)</td><td char="(" align="char">13 (100)</td><td char="(" align="char">26 (100)</td><td char="(" align="char">13 (100)</td><td char="(" align="char">13 (100)</td><td char="(" align="char">92 (100)</td></tr><tr><td align="left" colspan="7">Metavir fibrosis stage, <italic>n</italic> (%)</td></tr><tr><td align="left">&#x000a0;0: No fibrosis</td><td char="(" align="char">0</td><td char="(" align="char">0</td><td char="(" align="char">2 (8)</td><td char="(" align="char">2 (15)</td><td char="(" align="char">1 (8)</td><td char="(" align="char">5 (5)</td></tr><tr><td align="left">&#x000a0;1: Periportal fibrosis expansion</td><td char="(" align="char">18 (67)</td><td char="(" align="char">8 (62)</td><td char="(" align="char">16 (62)</td><td char="(" align="char">6 (46)</td><td char="(" align="char">8 (62)</td><td char="(" align="char">56 (61)</td></tr><tr><td align="left">&#x000a0;2: P-P septae (&#x0003e;1 septum)</td><td char="(" align="char">7 (26)</td><td char="(" align="char">3 (23)</td><td char="(" align="char">8 (31)</td><td char="(" align="char">4 (31)</td><td char="(" align="char">3 (23)</td><td char="(" align="char">25 (27)</td></tr><tr><td align="left">&#x000a0;3: P-C septae</td><td char="(" align="char">2 (7)</td><td char="(" align="char">2 (15)</td><td char="(" align="char">0</td><td char="(" align="char">1 (8)</td><td char="(" align="char">1 (8)</td><td char="(" align="char">6 (7)</td></tr><tr><td align="left">&#x000a0;4: Cirrhosis</td><td char="(" align="char">0</td><td char="(" align="char">0</td><td char="(" align="char">0</td><td char="(" align="char">0</td><td char="(" align="char">0</td><td char="(" align="char">0</td></tr></tbody></table><table-wrap-foot><p>All randomized patients who received any amount of study drug</p><p>
<italic>P-P</italic> portal&#x02013;portal, <italic>P-C</italic> portal-central</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec10"><title>Efficacy</title><sec id="Sec11"><title>On-treatment virologic response</title><p>During the first 3&#x02013;7&#x000a0;days of simeprevir administration, an initial rapid reduction in plasma HCV RNA was evident in all simeprevir groups (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). For analysis of the impact of simeprevir dose with regards to on-treatment virologic response, data were pooled by dose group (simeprevir 50&#x000a0;mg groups combined and 100&#x000a0;mg groups combined; Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Mean change from baseline in plasma HCV RNA through week 24. <italic>HCV</italic> hepatitis C virus, <italic>PR</italic> peginterferon&#x000a0;+&#x000a0;ribavirin, <italic>SD</italic> standard deviation, <italic>SMV</italic> simeprevir</p></caption><graphic xlink:href="535_2013_875_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>On-treatment and post-treatment virologic response (full analysis set)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">
<italic>n</italic>/<italic>N</italic> (%)</th><th align="left">SMV 50&#x000a0;mg combined (<italic>n</italic>&#x000a0;=&#x000a0;40)</th><th align="left">SMV 100&#x000a0;mg combined (<italic>n</italic>&#x000a0;=&#x000a0;39)</th><th align="left">PR48 (control) (<italic>n</italic>&#x000a0;=&#x000a0;13)</th></tr></thead><tbody><tr><td align="left">Undetectable HCV RNA at week 2</td><td char="(" align="char">11/39 (28)</td><td char="(" align="char">17/39 (44)</td><td char="(" align="char">0/13 (0)</td></tr><tr><td align="left">LS mean change in plasma HCV RNA from baseline at week 4 (95&#x000a0;% CI)<sup>a</sup>
</td><td char="(" align="char">&#x02212;5.2 (&#x02212;5.4, &#x02212;5.0)</td><td char="(" align="char">&#x02212;5.2 (&#x02212;5.4, &#x02212;5.0)</td><td char="(" align="char">&#x02212;2.9 (&#x02212;3.2, &#x02212;2.5)</td></tr><tr><td align="left">LS mean change of difference in plasma HCV RNA from baseline at week 4 (95&#x000a0;% CI)<sup>b</sup>
</td><td char="(" align="char">&#x02212;2.4 (&#x02212;2.7, &#x02212;2.0)</td><td char="(" align="char">&#x02212;2.4 (&#x02212;2.8, &#x02212;2.0)</td><td align="left"/></tr><tr><td align="left">RVR</td><td char="(" align="char">33/40 (83)</td><td char="(" align="char">35/39 (90)</td><td char="(" align="char">1/13 (8)</td></tr><tr><td align="left">cEVR</td><td char="(" align="char">39/40 (98<sup>*</sup>)</td><td char="(" align="char">36/39 (92<sup>*</sup>)</td><td char="(" align="char">7/13 (54)</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">SMV12/PR24 50&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;27)</th><th align="left">SMV24/PR24 50&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;13)</th><th align="left">SMV12/PR24 100&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;26)</th><th align="left">SMV24/PR24 100&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;13)</th><th align="left">PR48 (control) (<italic>n</italic>&#x000a0;=&#x000a0;13)</th></tr></thead><tbody><tr><td align="left" colspan="6">SVR24</td></tr><tr><td align="left">&#x000a0;All patients</td><td char="(" align="char">21/27 (78)</td><td char="(" align="char">10/13 (77)</td><td char="(" align="char">20/26 (77)</td><td char="(" align="char">12/13 (92)</td><td char="(" align="char">6/13 (46)</td></tr><tr><td align="left">&#x000a0;Patients who completed treatment at week 24<sup>c</sup>
</td><td char="(" align="char">20/24 (83)</td><td char="(" align="char">9/10 (90)</td><td char="(" align="char">18/20 (90)</td><td char="(" align="char">9/10 (90)</td><td align="left"/></tr><tr><td align="left">Viral relapse<sup>d</sup>
</td><td char="(" align="char">4/26 (15)</td><td char="(" align="char">2/12 (17)</td><td char="(" align="char">4/26 (15)</td><td char="(" align="char">1/13 (8)</td><td char="(" align="char">4/11 (36)</td></tr></tbody></table><table-wrap-foot><p>
<sup>a</sup>Least-squares mean change from baseline and their 95&#x000a0;% confidence intervals for each dose group</p><p>
<sup>b</sup>Difference in least-squares mean change from baseline from PR48 control and their 95&#x000a0;% confidence intervals for each dose group from ANCOVA model</p><p>
<sup>c</sup>Patients who completed treatment at week 24 as per RGT, excluding patients who discontinued treatment before week 24</p><p>
<sup>d</sup>The denominator is the number of patients with undetectable HCV RNA at the end of treatment</p><p>
<italic>cEVR</italic> complete early virologic response, undetectable HCV RNA at week 12 in treatment period, <italic>HCV</italic> hepatitis C virus, <italic>PR</italic> pegylated interferon alpha-2a and ribavirin, <italic>RVR</italic> rapid virologic response undetectable HCV RNA at week 4 of treatment, <italic>SVR24</italic> sustained virologic response 24&#x000a0;weeks after the end of treatment</p><p>*&#x000a0;<italic>P</italic>&#x000a0;&#x02264;&#x000a0;0.05 vs PR48 group; Fisher&#x02019;s exact test</p></table-wrap-foot></table-wrap></p><p>The mean HCV RNA change from baseline to week 4 was significantly greater in the simeprevir combined 50 and 100&#x000a0;mg groups than in the PR48 group; LS mean differences from the PR48 group were 2.4 for both simeprevir 50&#x000a0;mg combined and 100&#x000a0;mg combined [both of the least-squares mean difference values (95&#x000a0;% confidence interval) were below zero].</p><p>The majority of patients in the simeprevir 50&#x000a0;mg combined and 100&#x000a0;mg combined groups achieved RVR and cEVR (83&#x02013;90 and 92&#x02013;98&#x000a0;%, respectively), compared with rates of 8 and 54&#x000a0;%, respectively, in the PR48 group.</p></sec><sec id="Sec12"><title>Sustained virologic response</title><p>The SVR24 rate was higher in the simeprevir groups than in the PR48 group, with rates of 78, 77, 77, 92 and 46 in the SMV12/PR24 50&#x000a0;mg, SMV24/PR24 50&#x000a0;mg, SMV12/PR24 100&#x000a0;mg, SMV24/PR24 100&#x000a0;mg and PR48 groups, respectively (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Sustained virologic response rates (SVR24). <italic>PR</italic> peginterferon&#x000a0;+&#x000a0;ribavirin, <italic>SMV</italic> simeprevir</p></caption><graphic xlink:href="535_2013_875_Fig2_HTML" id="MO2"/></fig></p><p>All patients in the simeprevir groups, except for one patient in the SMV12/PR24 100&#x000a0;mg group, successfully completed treatment at week 24, as they met the RGT criteria. Among these patients, SVR24 rates ranged from 83 to 90&#x000a0;%.</p><p>All seven patients who discontinued the study during the follow-up period were classified as non-SVR, although four out of the seven patients had undetectable HCV RNA at the last visit before withdrawal.</p></sec><sec id="Sec13"><title>Viral breakthrough, viral relapse or treatment failure</title><p>One patient in the SMV12/PR24 50 mg group experienced viral breakthrough at week 20 after the HCV RNA level became undetectable from weeks 3 to 16. This patient had viral breakthrough during treatment with PegIFN&#x003b1;-2a/RBV, after the completion of triple therapy. No viral breakthrough was reported in the other simeprevir groups or the PR48 group.</p><p>Compared to the PR48 group (36&#x000a0;%), viral relapse rates were apparently lower in the simeprevir groups regardless of dose or duration (15, 17, 15 and 8&#x000a0;% in the SMV12/PR24 50&#x000a0;mg, SMV24/PR24 50&#x000a0;mg, SMV12/PR24 100 mg, and SMV24/PR24 100 mg group, respectively) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p>Among the patients in the simeprevir treatment groups, 20&#x000a0;% (16/79) did not achieve SVR24. The reasons for this were detectable HCV RNA at the end of treatment (two patients), viral relapse (11 patients), or missing HCV RNA results for patients at 24&#x000a0;weeks after they had achieved undetectable levels at the end of treatment (three patients).</p></sec><sec id="Sec14"><title>Viral population sequencing</title><p>No emerging mutations were observed in the selected HCV NS3 protease domain in the patient with viral breakthrough. Paired HCV NS3 sequence information (at baseline and time of relapse) was available for 10/11 simeprevir-treated relapsers, and emerging mutations in the NS3 protease domain (Q80R, R155Q, D169A, C, E, H and/or V, alone or in combination) were detected in six of these ten patients.</p></sec><sec id="Sec15"><title>Alanine aminotransferase</title><p>The proportion of simeprevir-treated patients who had ALT levels within the normal limit had increased from 57&#x000a0;% at baseline to 92&#x000a0;% at the end of treatment (per protocol analysis).</p></sec></sec><sec id="Sec16"><title>Safety</title><p>The rates of simeprevir and PegIFN&#x003b1;-2a/RBV discontinuation and PegIFN&#x003b1;-2a/RBV dose modification due to AEs were similar between the simeprevir groups and the PR48 group.</p><p>There was one death reported due to cerebral infarction in the SMV12/PR24 100&#x000a0;mg group. The patient was a 64-year-old female with hypertension but no other notable medical history. The death occurred approximately 3&#x000a0;weeks after the end of treatment and was therefore considered to be unrelated to simeprevir and PegIFN&#x003b1;-2a/RBV.</p><p>A summary of AEs is shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. There were no clinically relevant differences in the incidence of AEs across the groups and the majority of AEs were of grade 1 or 2 in severity according to the WHO toxicity grading predefined in the study protocol. Rash and arthralgia, which were slightly higher (&#x0003e;15&#x000a0;% numerical difference) in the simeprevir groups than in the PR48 group, were also grade 1 or 2 in severity.<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Summary of adverse events and changes in hemoglobin and total bilirubin levels across all treatment groups (safety population)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">
<italic>n</italic> (%)</th><th align="left">SMV12/PR24 50&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;27)</th><th align="left">SMV24/PR24 50&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;13)</th><th align="left">SMV12/PR24 100&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;26)</th><th align="left">SMV24/PR24 100&#x000a0;mg (<italic>n</italic>&#x000a0;=&#x000a0;13)</th><th align="left">All SMV (<italic>n</italic>&#x000a0;=&#x000a0;79)</th><th align="left">PR48 (<italic>n</italic>&#x000a0;=&#x000a0;13)</th></tr></thead><tbody><tr><td align="left" colspan="7">Adverse events</td></tr><tr><td align="left">&#x000a0;Discontinuation of all treatment due to adverse event<sup>a</sup>
</td><td char="(" align="char">1 (4)</td><td char="(" align="char">3 (23)</td><td char="(" align="char">3 (12)</td><td char="(" align="char">1 (8)</td><td char="(" align="char">8 (10)</td><td char="(" align="char">2 (15)</td></tr><tr><td align="left">&#x000a0;Discontinuation of simeprevir only due to adverse event</td><td char="(" align="char">1 (4)</td><td char="(" align="char">0</td><td char="(" align="char">3 (12)</td><td char="(" align="char">2 (15)</td><td char="(" align="char">6 (8)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Dose modification of PegIFN&#x003b1;-2a or RBV due to adverse event</td><td char="(" align="char">17 (63)</td><td char="(" align="char">8 (62)</td><td char="(" align="char">21 (81)</td><td char="(" align="char">12 (92)</td><td char="(" align="char">58 (73)</td><td char="(" align="char">11 (85)</td></tr><tr><td align="left">&#x000a0;Any serious adverse event</td><td char="(" align="char">0</td><td char="(" align="char">1 (8)</td><td char="(" align="char">3 (12)</td><td char="(" align="char">1 (8)</td><td char="(" align="char">5 (6)</td><td char="(" align="char">0</td></tr><tr><td align="left">&#x000a0;Death<sup>b</sup>
</td><td char="(" align="char">0</td><td char="(" align="char">0</td><td char="(" align="char">1 (8)</td><td char="(" align="char">0</td><td char="(" align="char">1 (1)</td><td char="(" align="char">0</td></tr><tr><td align="left" colspan="7">Common adverse events<sup>c</sup>
</td></tr><tr><td align="left">&#x000a0;White blood cell count decreased</td><td char="(" align="char">16 (59)</td><td char="(" align="char">10 (77)</td><td char="(" align="char">15 (58)</td><td char="(" align="char">12 (92)</td><td char="(" align="char">53 (67)</td><td char="(" align="char">10 (77)</td></tr><tr><td align="left">&#x000a0;Malaise</td><td char="(" align="char">17 (63)</td><td char="(" align="char">8 (62)</td><td char="(" align="char">16 (62)</td><td char="(" align="char">7 (54)</td><td char="(" align="char">48 (61)</td><td char="(" align="char">8 (62)</td></tr><tr><td align="left">&#x000a0;Neutrophil count decreased</td><td char="(" align="char">12 (44)</td><td char="(" align="char">10 (77)</td><td char="(" align="char">14 (54)</td><td char="(" align="char">12 (92)</td><td char="(" align="char">48 (61)</td><td char="(" align="char">9 (69)</td></tr><tr><td align="left">&#x000a0;Rash</td><td char="(" align="char">17 (63)</td><td char="(" align="char">8 (62)</td><td char="(" align="char">15 (58)</td><td char="(" align="char">8 (62)</td><td char="(" align="char">48 (61)</td><td char="(" align="char">6 (46)</td></tr><tr><td align="left">&#x000a0;Pyrexia</td><td char="(" align="char">18 (67)</td><td char="(" align="char">7 (54)</td><td char="(" align="char">10 (39)</td><td char="(" align="char">7 (54)</td><td char="(" align="char">42 (53)</td><td char="(" align="char">7 (54)</td></tr><tr><td align="left">&#x000a0;Headache</td><td char="(" align="char">14 (52)</td><td char="(" align="char">8 (62)</td><td char="(" align="char">13 (50)</td><td char="(" align="char">6 (46)</td><td char="(" align="char">41 (52)</td><td char="(" align="char">8 (62)</td></tr><tr><td align="left">&#x000a0;Hemoglobin decreased</td><td char="(" align="char">8 (30)</td><td char="(" align="char">7 (54)</td><td char="(" align="char">12 (46)</td><td char="(" align="char">7 (54)</td><td char="(" align="char">34 (43)</td><td char="(" align="char">6 (46)</td></tr><tr><td align="left">&#x000a0;Arthralgia</td><td char="(" align="char">9 (33)</td><td char="(" align="char">6 (46)</td><td char="(" align="char">7 (27)</td><td char="(" align="char">5 (39)</td><td char="(" align="char">27 (34)</td><td char="(" align="char">2 (15)</td></tr><tr><td align="left">&#x000a0;Alopecia</td><td char="(" align="char">11 (41)</td><td char="(" align="char">5 (39)</td><td char="(" align="char">6 (23)</td><td char="(" align="char">3 (23)</td><td char="(" align="char">25 (32)</td><td char="(" align="char">6 (46)</td></tr><tr><td align="left">&#x000a0;Anemia</td><td char="(" align="char">8 (30)</td><td char="(" align="char">5 (39)</td><td char="(" align="char">6 (23)</td><td char="(" align="char">5 (39)</td><td char="(" align="char">24 (30)</td><td char="(" align="char">5 (39)</td></tr><tr><td align="left">Protocol predefined rash/cutaneous reactions<sup>d</sup>
</td><td char="(" align="char">21 (78)</td><td char="(" align="char">8 (62)</td><td char="(" align="char">18 (69)</td><td char="(" align="char">8 (62)</td><td char="(" align="char">55 (70)</td><td char="(" align="char">8 (62)</td></tr><tr><td align="left">&#x000a0;Grade 1 or 2</td><td char="(" align="char">21 (78)</td><td char="(" align="char">8 (62)</td><td char="(" align="char">18 (69)</td><td char="(" align="char">8 (62)</td><td char="(" align="char">55 (70)</td><td char="(" align="char">8 (62)</td></tr><tr><td align="left">&#x000a0;Grade 3 or 4<sup>e</sup>
</td><td char="(" align="char">0</td><td char="(" align="char">0</td><td char="(" align="char">0</td><td char="(" align="char">0</td><td char="(" align="char">0</td><td char="(" align="char">0</td></tr><tr><td align="left" colspan="7">Hemoglobin and total bilirubin levels by grade<sup>f</sup>
</td></tr><tr><td align="left" colspan="7">Hemoglobin levels</td></tr><tr><td align="left">&#x000a0;Grade 1 (9.5&#x02013;10.5&#x000a0;g/dL)</td><td char="(" align="char">9 (33)</td><td char="(" align="char">4 (31)</td><td char="(" align="char">9 (35)</td><td char="(" align="char">5 (39)</td><td char="(" align="char">27 (34)</td><td char="(" align="char">8 (62)</td></tr><tr><td align="left">&#x000a0;Grade 2 (8.0&#x02013;9.4&#x000a0;g/dL)</td><td char="(" align="char">5 (19)</td><td char="(" align="char">4 (31)</td><td char="(" align="char">8 (31)</td><td char="(" align="char">6 (46)</td><td char="(" align="char">23 (29)</td><td char="(" align="char">3 (23)</td></tr><tr><td align="left">&#x000a0;Grade 3 (6.5&#x02013;7.9&#x000a0;g/dL) or 4 (&#x0003c;6.5&#x000a0;g/dL)</td><td char="(" align="char">0</td><td char="(" align="char">0</td><td char="(" align="char">0</td><td char="(" align="char">0</td><td char="(" align="char">0</td><td char="(" align="char">0</td></tr><tr><td align="left" colspan="7">Total bilirubin levels</td></tr><tr><td align="left">&#x000a0;Grade 1 (1.2&#x02013;1.5&#x000a0;mg/dL)</td><td char="(" align="char">10 (37)</td><td char="(" align="char">4 (31)</td><td char="(" align="char">10 (39)</td><td char="(" align="char">6 (46)</td><td char="(" align="char">30 (38)</td><td char="(" align="char">2 (15)</td></tr><tr><td align="left">&#x000a0;Grade 2 (1.6&#x02013;2.5&#x000a0;mg/dL)</td><td char="(" align="char">3 (11)</td><td char="(" align="char">3 (23)</td><td char="(" align="char">8 (31)</td><td char="(" align="char">2 (15)</td><td char="(" align="char">16 (20)</td><td char="(" align="char">1 (8)</td></tr><tr><td align="left">&#x000a0;Grade 3 (2.6&#x02013;5.0&#x000a0;mg/dL)</td><td char="(" align="char">1 (4)</td><td char="(" align="char">0</td><td char="(" align="char">2 (8)</td><td char="(" align="char">0</td><td char="(" align="char">3 (4)</td><td char="(" align="char">0</td></tr><tr><td align="left">&#x000a0;Grade 4 (&#x0003e;5.0&#x000a0;mg/dL)</td><td char="(" align="char">0</td><td char="(" align="char">0</td><td char="(" align="char">0</td><td char="(" align="char">1 (8)</td><td char="(" align="char">1 (1)</td><td char="(" align="char">0</td></tr></tbody></table><table-wrap-foot><p>
All randomized patients who received any amount of investigational drug</p><p>
<italic>PegIFN&#x003b1;-2a</italic> peginterferon alpha-2a, <italic>RBV</italic> ribavirin</p><p>
<sup>a</sup>Patients who discontinued PegIFN&#x003b1;-2a/RBV treatment regardless of completion or discontinuation of simeprevir</p><p>
<sup>b</sup>There was one death by cerebral infarction in the SMV12/PR24 100&#x000a0;mg group, which occurred 3&#x000a0;weeks after the end of treatment and was considered to be unrelated to the study medication</p><p>
<sup>c</sup>Common adverse events were those classified as occurring with an incidence of &#x0003e;30&#x000a0;% of patients in all the simeprevir groups</p><p>
<sup>d</sup>Rash/cutaneous reaction (except for pruritus without visible skin finding), which is considered to have a relationship of causality to any medication</p><p>
<sup>e</sup>Rashes with some characteristics, such as vesiculation, moist desquamation or ulceration were categorized as grade 3. Exfoliative dermatitis, mucous membrane involvement, erythema multiforme exudativum, Stevens&#x02013;Johnson syndrome or toxic epidermal necrosis were categorized as grade 4</p><p>
<sup>f</sup>According to modified World Health Organization toxicity grades. The worst grade during the treatment period for each patient was identified</p></table-wrap-foot></table-wrap></p><p>For protocol-predefined rash/cutaneous reactions (except for pruritus without visible skin findings) considered by the investigator to be caused by any medication, the incidence rate was similar between the simeprevir groups and the PR48 group, with no notable differences across the simeprevir groups and with no grade 3 or 4 events, such as Stevens-Johnson syndrome or toxic epidermal necrosis, reported (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). As for pruritus, which was reported in 19&#x000a0;% of the simeprevir-treated patients (compared to none in the PR group), all events were grade 1 or 2 in severity.</p><p>Incidences of anemia and decreased hemoglobin were similar in the simeprevir groups and the PR48 group, as were the rates of discontinuation and RBV dose reduction due to these two AEs. All were grade 1 or 2 and no notable differences were reported across the simeprevir groups. Of note, treatment with erythropoietin was not permitted in the study. Changes in hemoglobin levels from baseline were also similar across the groups and none of the patients had values &#x0003c;8&#x000a0;g/dL (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Mean hemoglobin and total bilirubin in patient plasma through week 48. Total bilirubin ULN&#x000a0;=&#x000a0;17.1&#x000a0;&#x003bc;mol/L. <italic>Scr</italic> screening visit, <italic>BL</italic> baseline visit, <italic>PR</italic> peginterferon&#x000a0;+&#x000a0;ribavirin, <italic>SD</italic> standard deviation, <italic>SMV</italic> simeprevir, <italic>ULN</italic> upper limit of normal</p></caption><graphic xlink:href="535_2013_875_Fig3_HTML" id="MO3"/></fig></p><p>Mild and transient increases in bilirubin levels (direct and indirect) were observed in the simeprevir groups during the first 2&#x000a0;weeks. Mean bilirubin values stabilized or decreased during continued treatment and returned to baseline values after week 12 in the SMV12/PR24 groups and week 24 in the SMV24/PR24 groups (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>b). These changes were not associated with increases in the laboratory parameters for ALT or aspartate aminotransferase. Four simeprevir-treated patients experienced grade 3 (2.6&#x02013;5.0&#x000a0;mg/dL) or 4 (&#x0003e;5.0 mg/dL) total bilirubin elevations during weeks 1 to 2 of treatment (the ratio direct/total bilirubin at the time point of the highest bilirubin value in these four patients were 26.5, 31.6, 60.7 and 17.5&#x000a0;%, respectively) and discontinued simeprevir in accordance with the treatment discontinuation criteria, which were predefined in the study protocol. All of these bilirubin elevations began to decrease before or immediately after the end of simeprevir treatment and returned to baseline after the end of simeprevir treatment. No particular changes (elevations) in other hepatic parameters or any clinically relevant symptoms were reported in these patients. No other clinically significant differences in laboratory parameters between the simeprevir groups and the PR48 group were observed.</p></sec></sec><sec id="Sec17" sec-type="discussion"><title>Discussion</title><p>This study was the first in treatment-na&#x000ef;ve Asian patients chronically infected with HCV genotype 1 and with high viral load, to investigate the efficacy, safety and pharmacokinetics of simeprevir as part of a treatment regimen including PegIFN&#x003b1;-2a and RBV. In this study, all patients were infected with HCV genotype 1b, reflecting the high prevalence of this subtype in Japan.</p><p>Results of the study indicated that once-daily simeprevir (50 and 100&#x000a0;mg) in combination with PegIFN&#x003b1;-2a/RBV significantly improved the SVR24 rate compared with PegIFN&#x003b1;-2a/RBV alone in this patient population.</p><p>In this study, an RGT strategy was employed to allow individualized shortening of PegIFN&#x003b1;/RBV treatment duration to 24&#x000a0;weeks, based on early viral kinetics. According to the RGT criteria, the majority of simeprevir patients were eligible to stop all treatment at week 24. Furthermore, these patients had high SVR24 rates (83&#x02013;90&#x000a0;%). This indicates that an RGT approach is also beneficial for patients in Japan. Shorter overall treatment duration is highly desirable as it reduces the length of exposure to PegIFN&#x003b1;-2a/RBV, thereby potentially reducing the duration of AEs experienced by the patient, and is also a cost-effective alternative to standard-duration PegIFN&#x003b1;/RBV therapy [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p>During the first 3&#x000a0;days of dosing, both 50 and 100&#x000a0;mg doses of simeprevir demonstrated an initial rapid reduction in HCV RNA. Subsequent reduction in HCV&#x000a0;RNA was less pronounced, and by week 4, the LS mean HCV RNA decline from baseline was &#x02212;5.2 log<sub>10</sub>&#x000a0;IU/mL in both the simeprevir 50&#x000a0;mg combined and 100&#x000a0;mg combined groups, compared with &#x02212;2.9 log<sub>10</sub>&#x000a0;IU/mL in the PR48 group. This biphasic reduction in HCV RNA was consistent with viral kinetics observed in a previous proof-of-concept simeprevir study (OPERA-1) [<xref ref-type="bibr" rid="CR23">23</xref>] and other potent DAAs. In all simeprevir groups, RVR was highly predictive of SVR. Following high RVR rates (83&#x02013;90&#x000a0;%, compared with 8&#x000a0;% in the PR48 group), simeprevir-treated patients achieved high SVR24 rates (77&#x02013;92&#x000a0;%, compared with 46&#x000a0;% in the PR48 group), accompanied by low rates of viral relapse (8&#x02013;17&#x000a0;%, compared with 36&#x000a0;% in the PR48 group). The response rates in the PR48 group are consistent with previous reports [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p><p>No viral breakthrough was reported in the simeprevir 100&#x000a0;mg groups during the treatment period. In addition, the on-treatment virologic response rate in the early treatment phase (weeks 2 to 4) was slightly higher in the simeprevir combined 100&#x000a0;mg group compared with the combined 50&#x000a0;mg group (e.g., 44&#x000a0;% of the patients in the simeprevir 100&#x000a0;mg group had undetectable HCV RNA, versus 28&#x000a0;% in the simeprevir 50&#x000a0;mg group at week 2). The on-treatment response was not affected by the duration of simeprevir treatment across dose group (RVR rate of 85, 77, 89 and 92&#x000a0;%; cEVR rate of 100, 92, 89 and 100&#x000a0;%, in the SMV12/PR24 50&#x000a0;mg, SMV24/PR24 50&#x000a0;mg, SMV12/PR24 100&#x000a0;mg and SMV24/PR24 100&#x000a0;mg groups, respectively), and no clear relationship between relapse rate and duration of simeprevir treatment was observed. Therefore, the simeprevir 100&#x000a0;mg dose with a 12-week duration as triple therapy has been selected to be taken forward into Phase III trials.</p><p>In addition to the notable virologic response, the study demonstrated greater increases from baseline to the end of treatment in the proportion of simeprevir-treated patients (per protocol population) with normal ALT levels.</p><p>Overall, these results are consistent with previous simeprevir trials which investigated HCV genotype 1-infected, treatment-na&#x000ef;ve patients, conducted mainly in the USA and Europe [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p>In simeprevir-treated patients with viral relapse for whom sequence information was available, emerging mutations in the NS3 protease domain (Q80R, R155Q, D168A/C/E/H and V, alone or in combination) were detected around the time of viral relapse in 6/10 patients. Mutations at these positions have been previously identified in vitro [<xref ref-type="bibr" rid="CR29">29</xref>]. Considering the dominance of the HCV genotype 1b in Japan, further evaluation of emerging mutations is required.</p><p>There were no notable differences in incidence of AEs or discontinuations due to AEs between groups receiving triple therapy of simeprevir with PegIFN&#x003b1;-2a/RBV and those receiving PegIFN&#x003b1;-2a/RBV alone. In contrast to the first-generation PIs [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR19">19</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>], no severe anemia or severe rash/cutaneous reactions (including, though not limited to, Stevens-Johnson syndrome or toxic epidermal necrosis) were reported in this study. Except for bilirubin levels, there were no significant changes in laboratory values including hemoglobin, neutrophil count and platelet count. Mild, transient increases in bilirubin (direct, indirect and total) levels were observed in simeprevir-treated patients, though these were not clinically significant or accompanied by increases in other hepatic function parameters. These bilirubin level elevations were grade 3 (2.6&#x02013;5.0&#x000a0;mg/dL) or 4 (&#x0003e;5.0&#x000a0;mg/dL) in four simeprevir-treated patients, which led to the discontinuation of simeprevir in these individuals. The bilirubin levels began to decrease before the end of simeprevir treatment and returned to baseline after the end of simeprevir treatment. In vitro studies indicated that this may be due to the inhibition of OATP1B1 and MRP2 transporters by simeprevir, as both have a role in bilirubin clearance [<xref ref-type="bibr" rid="CR30">30</xref>]. However, it is not anticipated that inhibition of these transporters will affect dosing, efficacy or safety in ongoing studies.</p><p>In conclusion, in Japanese treatment-na&#x000ef;ve patients infected with HCV genotype 1b with high viral load, treatment with oral, once-daily simeprevir in combination with PegIFN&#x003b1;-2a and RBV, regardless of simeprevir dose regimen (50 or 100&#x000a0;mg QD, for 12 or 24&#x000a0;weeks), demonstrated potent antiviral activity and high SVR rates, and shortened the overall treatment duration in the majority of patients. Simeprevir was well tolerated, with no additional side effects or incremental adverse events. The mild and reversible bilirubin elevation was asymptomatic and not accompanied by elevation of other hepatic parameters.</p><p>Novel DAAs are expected to continue the improvement of HCV treatment (i.e., further improved safety profile, more convenient dosing regimens, and reduced resistance), started by the addition of the first generation of protease inhibitors to PegIFN/RBV combination therapy. Based on the data provided by this Phase II DRAGON study, the Phase III CONCERTO trials will shed further light on the treatment of chronic HCV genotype-1 infection in treatment-na&#x000ef;ve and -experienced patients in Japan.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec18"><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="535_2013_875_MOESM1_ESM.docx"><caption><p>Supplementary material 1 (DOCX 103&#x000a0;kb)</p></caption></media></supplementary-material></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>AE</term><def><p>Adverse event</p></def></def-item><def-item><term>ALT</term><def><p>Alanine aminotransferase</p></def></def-item><def-item><term>CI</term><def><p>Confidence interval</p></def></def-item><def-item><term>DAA</term><def><p>Direct-acting antiviral agent</p></def></def-item><def-item><term>DRAGON</term><def><p>The Dose and duration Ranging study of Antiviral agent TMC435 in Genotype One HCV treatment-Na&#x000ef;ve patients</p></def></def-item><def-item><term>HCC</term><def><p>Hepatocellular carcinoma</p></def></def-item><def-item><term>HCV</term><def><p>Hepatitis C virus</p></def></def-item><def-item><term>LS</term><def><p>Least squares</p></def></def-item><def-item><term>QD</term><def><p>Once daily</p></def></def-item><def-item><term>PegIFN&#x003b1;-2a</term><def><p>Peginterferon &#x003b1;-2a</p></def></def-item><def-item><term>PI</term><def><p>Protease inhibitor</p></def></def-item><def-item><term>RBV</term><def><p>Ribavirin</p></def></def-item><def-item><term>RGT</term><def><p>Response-guided therapy</p></def></def-item><def-item><term>RNA</term><def><p>Ribonucleic acid</p></def></def-item><def-item><term>SAE</term><def><p>Serious adverse event</p></def></def-item><def-item><term>SVR24</term><def><p>Sustained virologic response 24&#x000a0;weeks after end of treatment</p></def></def-item></def-list></def-list></glossary><ack><p>The authors would like to thank all patients, their families, investigators and their staff in the following 25 study sites for completion of the study. The principal investigators for the TMC435-C215 study sites are listed below (alphabetical order): Akio Ido (Kagoshima University Medical and Dental Hospital), Eiji Mita (National Hospital Organization Osaka National Hospital), Harumasa Yoshihara (Osaka Rosai Hospital), Hideki Hagiwara (Kansai Rosai Hospital), Hideyuki Nomura (Shin-Kokura Hospital), Hiromitsu Kumada (Toranomon Hospital), Hiroshi Yatsuhashi (National Hospital Organization, Nagasaki Medical Center), Kazuhiro Katayama (Osaka Medical Center for Cancer and Cardiovascular Diseases), Kazushi Numata (Yokohama City University Medical Center), Kiyohide Kioka (Osaka City General Hospital), Kiyomi Yasuda (Kiyokawa Hospital), Masatoshi Kudo (Kinki University Hospital), Namiki Izumi (Musashino Red Cross Hospital), Norifumi Kawada (Osaka City University Hospital), Syouichi Takahashi (Hiroshima University Hospital), Syuhei Nishiguchi (The Hospital of Hyogo College of Medicine), Takayoshi Ito (Showa University Hospital), Takeji Umemura (Shinshu University Hospital), Tatsuya Ide (Kurume University Hospital), Tetsuo Takehara (Osaka University Hospital), Toshifumi Ito (Osaka Koseinenkin Hospital), Toshihide Shima (Saiseikai Suita Hospital), Yoichi Hiasa (Ehime University Hospital), Yoshito Itoh (University Hospital, Kyoto Prefectural University of Medicine), Yoshiyasu Karino (Sapporo Kosei General Hospital, Hokkaido). The DRAGON study was funded by Janssen Pharmaceutical K.K. Medical writing support was provided by Bethan Hahn, PhD, at Complete Medical Communications, and was funded by Janssen Research &#x00026; Development.</p><sec id="d30e2089"><title>Conflict of interest</title><p>Norio Hayashi has no conflict of interest. Chiharu Seto, Mai Kato, Yuji Komada, and Shoichiro Goto are employees of Janssen Pharmaceutical K.K.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavanchy</surname><given-names>D</given-names></name></person-group><article-title>The global burden of hepatitis C</article-title><source>Liver Int</source><year>2009</year><volume>29</volume><issue>Suppl 1</issue><fpage>74</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1111/j.1478-3231.2008.01934.x</pub-id><pub-id pub-id-type="pmid">19207969</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghany</surname><given-names>MG</given-names></name><name><surname>Strader</surname><given-names>DB</given-names></name><name><surname>Thomas</surname><given-names>DL</given-names></name><name><surname>Seeff</surname><given-names>LB</given-names></name></person-group><article-title>Diagnosis, management, and treatment of hepatitis C: an update</article-title><source>Hepatology</source><year>2009</year><volume>49</volume><fpage>1335</fpage><lpage>1374</lpage><pub-id pub-id-type="doi">10.1002/hep.22759</pub-id><pub-id pub-id-type="pmid">19330875</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordenstedt</surname><given-names>H</given-names></name><name><surname>White</surname><given-names>DL</given-names></name><name><surname>El-Serag</surname><given-names>HB</given-names></name></person-group><article-title>The changing pattern of epidemiology in hepatocellular carcinoma</article-title><source>Dig Liver Dis</source><year>2010</year><volume>42</volume><issue>Suppl 3</issue><fpage>S206</fpage><lpage>S214</lpage><pub-id pub-id-type="doi">10.1016/S1590-8658(10)60507-5</pub-id><pub-id pub-id-type="pmid">20547305</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikai</surname><given-names>I</given-names></name><name><surname>Arii</surname><given-names>S</given-names></name><name><surname>Okazaki</surname><given-names>M</given-names></name><name><surname>Okita</surname><given-names>K</given-names></name><name><surname>Omata</surname><given-names>M</given-names></name><name><surname>Kojiro</surname><given-names>M</given-names></name><etal/></person-group><article-title>Report of the 17th nationwide follow-up survey of primary liver cancer in Japan</article-title><source>Hepatol Res</source><year>2007</year><volume>37</volume><fpage>676</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1111/j.1872-034X.2007.00119.x</pub-id><pub-id pub-id-type="pmid">17617112</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuen</surname><given-names>MF</given-names></name><name><surname>Hou</surname><given-names>JL</given-names></name><name><surname>Chutaputti</surname><given-names>A</given-names></name></person-group><article-title>Hepatocellular carcinoma in the Asia pacific region</article-title><source>J Gastroenterol Hepatol</source><year>2009</year><volume>24</volume><fpage>346</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1746.2009.05784.x</pub-id><pub-id pub-id-type="pmid">19220670</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>H</given-names></name><name><surname>Ueda</surname><given-names>T</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name></person-group><article-title>Changing trends in hepatitis C infection over the past 50&#x000a0;years in Japan</article-title><source>Intervirology</source><year>2010</year><volume>53</volume><fpage>39</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1159/000252782</pub-id><pub-id pub-id-type="pmid">20068339</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>European Association for the Study of the Liver</collab></person-group><article-title>EASL clinical practice guidelines: management of hepatitis C virus infection</article-title><source>J Hepatol</source><year>2011</year><volume>55</volume><fpage>245</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2011.02.023</pub-id><pub-id pub-id-type="pmid">21371579</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arase</surname><given-names>Y</given-names></name><name><surname>Kumada</surname><given-names>H</given-names></name></person-group><article-title>Treatment strategy for chronic hepatitis C in Japan</article-title><source>Nihon Rinsho</source><year>2011</year><volume>69</volume><issue>Suppl 4</issue><fpage>180</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">22096915</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izumi</surname><given-names>N</given-names></name></person-group><article-title>Diagnostic and treatment algorithm of the Japanese society of hepatology: a consensus-based practice guideline</article-title><source>Oncology</source><year>2010</year><volume>78</volume><issue>Suppl 1</issue><fpage>78</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1159/000315234</pub-id><pub-id pub-id-type="pmid">20616588</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manns</surname><given-names>MP</given-names></name><name><surname>McHutchison</surname><given-names>JG</given-names></name><name><surname>Gordon</surname><given-names>SC</given-names></name><name><surname>Rustgi</surname><given-names>VK</given-names></name><name><surname>Shiffman</surname><given-names>M</given-names></name><name><surname>Reindollar</surname><given-names>R</given-names></name><etal/></person-group><article-title>Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial</article-title><source>Lancet</source><year>2001</year><volume>358</volume><fpage>958</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(01)06102-5</pub-id><pub-id pub-id-type="pmid">11583749</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fried</surname><given-names>MW</given-names></name><name><surname>Shiffman</surname><given-names>ML</given-names></name><name><surname>Reddy</surname><given-names>KR</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Marinos</surname><given-names>G</given-names></name><name><surname>Gon&#x000e7;ales</surname><given-names>FL</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><fpage>975</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa020047</pub-id><pub-id pub-id-type="pmid">12324553</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadziyannis</surname><given-names>SJ</given-names></name><name><surname>Sette</surname><given-names>H</given-names><suffix>Jr</suffix></name><name><surname>Morgan</surname><given-names>TR</given-names></name><name><surname>Balan</surname><given-names>V</given-names></name><name><surname>Diago</surname><given-names>M</given-names></name><name><surname>Marcellin</surname><given-names>P</given-names></name><etal/></person-group><article-title>Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose</article-title><source>Ann Intern Med</source><year>2004</year><volume>140</volume><fpage>346</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-140-5-200403020-00010</pub-id><pub-id pub-id-type="pmid">14996676</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bacon</surname><given-names>BR</given-names></name><name><surname>Gordon</surname><given-names>SC</given-names></name><name><surname>Lawitz</surname><given-names>E</given-names></name><name><surname>Marcellin</surname><given-names>P</given-names></name><name><surname>Vierling</surname><given-names>JM</given-names></name><name><surname>Zeuzem</surname><given-names>S</given-names></name><etal/></person-group><article-title>Boceprevir for previously treated chronic HCV genotype 1 infection</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><fpage>1207</fpage><lpage>1217</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1009482</pub-id><pub-id pub-id-type="pmid">21449784</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwo</surname><given-names>PY</given-names></name><name><surname>Lawitz</surname><given-names>EJ</given-names></name><name><surname>McCone</surname><given-names>J</given-names></name><name><surname>Schiff</surname><given-names>ER</given-names></name><name><surname>Vierling</surname><given-names>JM</given-names></name><name><surname>Pound</surname><given-names>D</given-names></name><etal/></person-group><article-title>Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial</article-title><source>Lancet</source><year>2010</year><volume>376</volume><fpage>705</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)60934-8</pub-id><pub-id pub-id-type="pmid">20692693</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McHutchison</surname><given-names>JG</given-names></name><name><surname>Manns</surname><given-names>MP</given-names></name><name><surname>Muir</surname><given-names>AJ</given-names></name><name><surname>Terrault</surname><given-names>NA</given-names></name><name><surname>Jacobson</surname><given-names>IM</given-names></name><name><surname>Afdhal</surname><given-names>NH</given-names></name><etal/></person-group><article-title>Telaprevir for previously treated chronic HCV infection</article-title><source>N Engl J Med</source><year>2010</year><volume>362</volume><fpage>1292</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0908014</pub-id><pub-id pub-id-type="pmid">20375406</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobson</surname><given-names>IM</given-names></name><name><surname>McHutchison</surname><given-names>JG</given-names></name><name><surname>Dusheiko</surname><given-names>G</given-names></name><name><surname>Di Bisceglie</surname><given-names>AM</given-names></name><name><surname>Reddy</surname><given-names>KR</given-names></name><name><surname>Bzowej</surname><given-names>NH</given-names></name><etal/></person-group><article-title>Telaprevir for previously untreated chronic hepatitis C virus infection</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><fpage>2405</fpage><lpage>2416</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1012912</pub-id><pub-id pub-id-type="pmid">21696307</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>N</given-names></name><name><surname>Okanoue</surname><given-names>T</given-names></name><name><surname>Tsubouchi</surname><given-names>H</given-names></name><name><surname>Toyota</surname><given-names>J</given-names></name><name><surname>Chayama</surname><given-names>K</given-names></name><name><surname>Kumada</surname><given-names>H</given-names></name></person-group><article-title>Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C</article-title><source>J Viral Hepat</source><year>2012</year><volume>19</volume><fpage>e134</fpage><lpage>e142</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2893.2011.01528.x</pub-id><pub-id pub-id-type="pmid">22239511</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumada</surname><given-names>H</given-names></name><name><surname>Toyota</surname><given-names>J</given-names></name><name><surname>Okanoue</surname><given-names>T</given-names></name><name><surname>Chayama</surname><given-names>K</given-names></name><name><surname>Tsubouchi</surname><given-names>H</given-names></name><name><surname>Hayashi</surname><given-names>N</given-names></name></person-group><article-title>Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan</article-title><source>J Hepatol</source><year>2012</year><volume>56</volume><fpage>78</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2011.07.016</pub-id><pub-id pub-id-type="pmid">21827730</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poordad</surname><given-names>F</given-names></name><name><surname>McCone</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Bacon</surname><given-names>BR</given-names></name><name><surname>Bruno</surname><given-names>S</given-names></name><name><surname>Manns</surname><given-names>MP</given-names></name><name><surname>Sulkowski</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Boceprevir for untreated chronic HCV genotype 1 infection</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><fpage>1195</fpage><lpage>1206</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1010494</pub-id><pub-id pub-id-type="pmid">21449783</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hezode</surname><given-names>C</given-names></name></person-group><article-title>Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice</article-title><source>Liver Int</source><year>2012</year><volume>32</volume><issue>Suppl 1</issue><fpage>32</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1111/j.1478-3231.2011.02707.x</pub-id><pub-id pub-id-type="pmid">22212569</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherman</surname><given-names>KE</given-names></name><name><surname>Flamm</surname><given-names>SL</given-names></name><name><surname>Afdhal</surname><given-names>NH</given-names></name><name><surname>Nelson</surname><given-names>DR</given-names></name><name><surname>Sulkowski</surname><given-names>MS</given-names></name><name><surname>Everson</surname><given-names>GT</given-names></name><etal/></person-group><article-title>Response-guided telaprevir combination treatment for hepatitis C virus infection</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><fpage>1014</fpage><lpage>1024</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1014463</pub-id><pub-id pub-id-type="pmid">21916639</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I et al. TMC435 in combination with peginterferon and ribavirin in treatment-na&#x000ef;ve HCV genotype 1 patients: final analysis of the PILLAR phase IIb study. In: Abstract presented at the American Association for the Study of Liver Disease (AASLD), San Francisco, CA, USA, 4&#x02013;8 November, 2011.</mixed-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manns</surname><given-names>M</given-names></name><name><surname>Reesink</surname><given-names>H</given-names></name><name><surname>Berg</surname><given-names>T</given-names></name><name><surname>Dusheiko</surname><given-names>G</given-names></name><name><surname>Flisiak</surname><given-names>R</given-names></name><name><surname>Marcellin</surname><given-names>P</given-names></name><etal/></person-group><article-title>Rapid viral response of once-daily TMC435 plus peginterferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial</article-title><source>Antivir Ther</source><year>2011</year><volume>16</volume><fpage>1021</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.3851/IMP1894</pub-id><pub-id pub-id-type="pmid">22024518</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Sekar V, Vis P, Lenz O, Meyvisch P, Peeters M, De Smedt G. Pharmacokinetic-pharmacodynamic (PK-PD) analyses of TMC435 in treatment-naive hepatitis C (HCV)-infected patients in the OPERA-1 study. Poster 1075 presented at the 45th Annual Meeting of the European Association for the Study of the Liver, 14&#x02013;18 April, Vienna, Austria, 2010.</mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW et al. TMC435 with peginterferon and ribavirin in treatment-experienced HCV genotype 1 patients: the ASPIRE study, a randomised Phase IIb trial. Abstract A-455-0022-00482 presented at the Annual Meeting of the European Association for the Study of the Liver (EASL), Barcelona, Spain, 18&#x02013;22 April, 2012.</mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Verloes R, Shishido A (2009) Phase I safety and PK of TMC435 in healthy volunteers and safety, PK and short-term efficacy in chronic hepatitis C infected individuals. Abstract O-32 presented at the Japanese Hepatology Congress, Kobe, Japan, 4&#x02013;5 June, 2009.</mixed-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>KR</given-names></name><name><surname>Lin</surname><given-names>F</given-names></name><name><surname>Zoulim</surname><given-names>F</given-names></name></person-group><article-title>Response-guided and -unguided treatment of chronic hepatitis C</article-title><source>Liver Int</source><year>2012</year><volume>32</volume><issue>Suppl 1</issue><fpage>64</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1111/j.1478-3231.2011.02713.x</pub-id><pub-id pub-id-type="pmid">22212575</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akuta</surname><given-names>N</given-names></name><name><surname>Suzuki</surname><given-names>F</given-names></name><name><surname>Hirakawa</surname><given-names>M</given-names></name><name><surname>Kawamura</surname><given-names>Y</given-names></name><name><surname>Yatsuji</surname><given-names>H</given-names></name><name><surname>Sezaki</surname><given-names>H</given-names></name><etal/></person-group><article-title>A matched case-controlled study of 48 and 72&#x000a0;weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response</article-title><source>J Med Virol</source><year>2009</year><volume>81</volume><fpage>452</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1002/jmv.21400</pub-id><pub-id pub-id-type="pmid">19152407</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Lenz O, Vijgen L, Lin T-I, Verbinnen T, Berke JM, Meyvisch P, Simmen K, Fanning G. Analysis of the NS3 region in HCV genotype 1-infected patients treated with 5-day monotherapy of TMC435 in a Phase 1 study. In: 16th International Symposium on Hepatitis C Virus and Related Viruses, 3&#x02013;7 October, Nice, France 2009; Poster P-247.</mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Huisman MT, Snoeys J, Monbaliu J, Martens M, Sekar V, Raoof A. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. Poster 278 presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, USA, October 29-November 2, 2010.</mixed-citation></ref></ref-list></back></article>